NCT03831555 is a NA clinical trial of PREP-C in Hepatitis C, sponsored by Emory University.

Who is sponsoring NCT03831555?

NCT03831555 is sponsored by Emory University.

What drugs are being tested in NCT03831555?

Interventions in NCT03831555: PREP-C.

What condition does NCT03831555 study?

NCT03831555 studies Hepatitis C.

Is NCT03831555 still recruiting?

NCT03831555 is currently completed. Last updated 6 February 2019.

Last reviewed 2019-02-06 · How we verify

NCT03831555

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tool to Improve Treatment Adherence and Outcomes at Grady Liver Clinic

Completed NA Last updated 6 February 2019

What this trial tests

NA trial testing PREP-C in Hepatitis C in 100 participants. Completed in 30 June 2018.

Timeline

5 June 2017

Primary endpoint
1 May 2018

30 June 2018

Quick facts

Lead sponsor	Emory University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	100
Start date	5 June 2017
Primary completion	1 May 2018
Estimated completion	30 June 2018
Sites	1 location across United States

Drugs / interventions tested

PREP-C

Conditions studied

Hepatitis C — all drugs for Hepatitis C →

Sponsor

Emory University

Who can join

18 and older, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to learn more about what psychological and social factors affect people in how they take their hepatitis C medications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of PREP-C

Trials testing the same drug.

NCT03581383 — Community Access, Retention in Care, and Engagement for Hepatitis C Treatment · NA · completed

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other Emory University trials

Trials by the same sponsor.

NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03831555 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 6 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03831555.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing